Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.

ABSTRACT:

Background

The prognostic value of BRAF and KRAS mutations within microsatellite-unstable (MSI) and microsatellite-stable (MSS) subgroups of resected colon carcinoma patients remains controversial. We examined this question in prospectively collected biospecimens from stage III colon cancer with separate analysis of MSI and MSS tumors from patients receiving adjuvant FOLFOX +/- cetuximab in two adjuvant therapy trials.

Methods

Three groups were defined: BRAF Mutant, KRAS Mutant, and double wild-type. The analytic strategy involved estimation of study-specific effects, assessment of homogeneity of results, and then analysis of pooled data as no differences in patient outcome were found between treatment arms in both trials. Associations of mutations with patient outcome were

SUBMITTER: Taieb J 

PROVIDER: S-EPMC6075212 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature